Large Cap
Drug Manufacturers - General
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
Gilead Sciences
GILD
$190B
| $190B | $153.57 | 1.88% |
|
2
Novo Nordisk
NVO
$172B
| $172B | $39.06 | 0.74% |
|
3
Pfizer
PFE
$170B
| $170B | $29.85 | 0.86% |
|
4
Bristol-Myers Squibb
BMY
$125B
| $125B | $61.12 | 0.91% |
|
5
GSK
GSK
$100B
| $100B | $50.02 | 1.2% |
|
6
Sanofi
SNY
$98.2B
| $98.2B | $40.97 | 1.04% |
|
7
Biogen
BIIB
$35.6B
| $35.6B | $240.98 | 0.87% |
|
Large Cap Drug Manufacturers - General Stocks at a Glance
Large drug manufacturers sell diversified portfolios of branded medicines backed by deep development pipelines. Patent lives set the clock: blockbuster franchises fund the R&D and acquisitions needed to outrun expirations, supporting durable margins and dividends.
There are 7 large cap Drug Manufacturers - General stocks — companies in the Drug Manufacturers - General industry with a market cap between $10B and $200B — worth a combined $892B.
The largest by market cap are Gilead Sciences (GILD) at $190B, Novo Nordisk (NVO) at $172B and Pfizer (PFE) at $170B.
Among institutional investors, Novo Nordisk (NVO) drew the most net new fund positions in Q2 2026: 216 funds opened new positions, taking total fund holders up 78 (6.1%) quarter-over-quarter.
- Combined market cap: $892B across 7 stocks.
- Large Cap: market cap between $10B and $200B.
- Largest constituent: Gilead Sciences (GILD), $190B market cap.
- Most net new fund positions in Q2 2026: Novo Nordisk (NVO), +78 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.